Format

Send to

Choose Destination
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):325-329.

Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis

Author information

1
Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
2
Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran. Email: mahmadvand@sina.tums.ac.ir

Abstract

The RUNX1 (AML1) gene is a relatively infrequent mutational target in cases of acute myeloid leukemia (AML). Previous work indicated that RUNX1 mutations can have pathological and prognostic implications. To evaluate prognostic value, we conducted a meta-analysis of 4 previous published works with data for survival according to RUNX1 mutation status. Pooled hazard ratios for overall survival and disease-free survival were 1.55 (95% confidence interval (CI) = 1.11–2.15; p-value = 0.01) and 1.76 (95% CI = 1.24–2.52; p-value = 0.002), respectively, for cases positive for RUNX1 mutations. This evidence supports clinical implications of RUNX1 mutations in the development and progression of AML cases and points to the possibility of a distinct category within the newer WHO classification. Though it must be kept in mind that the present work was based on data extracted from observational studies, the findings suggest that the RUNX1 status can contribute to risk-stratification and decision-making in management of AML.

KEYWORDS:

Acute myeloid leukemia; AML1/RUNX1 mutation; prognosis; meta−analysis

PMID:
29479958
PMCID:
PMC5980915
DOI:
10.22034/APJCP.2018.19.2.325
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Asian Pacific Organization for Cancer Prevention Icon for PubMed Central
Loading ...
Support Center